Search - tctmd.com

Displaying 1 - 20 of 57

Sort: Relevancy | Date

News Conference News ESC 2025

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

L.A. McKeown

September 05, 2025

News Conference News VIVA 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

L.A. McKeown

November 11, 2024

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

L.A. McKeown

November 01, 2024

News Conference News CRT 2024

CLIPPER: Emphasis on Faster Revascularization Could Change CLTI Care

L.A. McKeown

March 20, 2024

News Opinion CV Team Dispatch

January 2024 Dispatch for the CV Team

L.A. McKeown

January 01, 2024

News Conference News TCT 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

L.A. McKeown

October 24, 2023

News Opinion CV Team Dispatch

September 2023 News Roundup

L.A. McKeown

September 01, 2023

News Conference News LINC 2023

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

L.A. McKeown

June 21, 2023

News Daily News

Only Half of Revascularized PAD Patients Receive GDMT

L.A. McKeown

February 14, 2023

News Daily News

Top Endovascular News of 2022

L.A. McKeown

January 03, 2023

News Conference News

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

L.A. McKeown

November 18, 2022

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

L.A. McKeown

November 07, 2022

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

L.A. McKeown

November 03, 2022

News Opinion CV Team Dispatch

September 2022 News Roundup

L.A. McKeown

September 01, 2022

News Conference News ESC 2022

DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark

L.A. McKeown

August 30, 2022

News Daily News

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

L.A. McKeown

June 01, 2022

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

L.A. McKeown

October 12, 2021

News Opinion CV Team Dispatch

September 2021 News Roundup

L.A. McKeown

September 01, 2021

News Conference News ACC 2021

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

L.A. McKeown

May 16, 2021

News Daily News

Vascular Experts Say It’s Time to Let Paclitaxel Out of Regulatory Jail

L.A. McKeown

April 22, 2021

Advertisement

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

CLIPPER: Emphasis on Faster Revascularization Could Change CLTI Care

January 2024 Dispatch for the CV Team

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

September 2023 News Roundup

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

Only Half of Revascularized PAD Patients Receive GDMT

Top Endovascular News of 2022

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

September 2022 News Roundup

DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

September 2021 News Roundup

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

Vascular Experts Say It’s Time to Let Paclitaxel Out of Regulatory Jail

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content